TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): review decision - August 2015
The Institute proposed that the guidance should move to the static list of technology appraisals.
After consideration of all of the comments received during the Review Consultation, the Technology Appraisals programme has decided to proceed with this proposal.
Consequently, TA257 will move to the static list of technology appraisals. Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.
This page was last updated: 11 August 2015